The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

While there was no change in disability-free survival, the results should impact guidelines, says François Mach.

SWITCH-SWEDEHEART’s unique design randomized healthcare regions but wasn’t a head-to-head comparison with ticagrelor.

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

The lack of impact on outcomes was surprising, says the investigator, though the FAST-CTCA trial may still come through.

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...

This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...

Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

As the first trial of these valve interventions to impact HF hospitalization and mortality, it “feels like a COAPT-like ...

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

While there’s no harm in discontinuing for patients who’ve yet to develop ASCVD by age 75, the trial also found no clear ...

An intervention in rural China continued to impact hypertension, CV events, and dementia risk 4 years after it ended.